Can we improve upon the international index?

Annals of Oncology

Volumn 8, Issue SUPPL. 1, 1997, Pages

  Shipp, M A ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

aggressive non Hodgkin's lymphoma; immune response; karyotype; prognosis

Indexed keywords

CANCER IMMUNOLOGY; CONFERENCE PAPER; HUMAN; IMMUNOPHENOTYPING; INTERNATIONAL COOPERATION; KARYOTYPE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; STANDARDIZATION;

EID: 0031009757     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/8.suppl_1.S43     Document Type: Conference Paper

References (62)

1. Shipp M, Harris N, Mauch P. Non-Hodgkin's lymphomas. In DeVita VT (ed): Principles and Practice of Oncology, 5th ed. Philadelphia: J. B. Lippincott (in press).
2. Carbone P, Kaplan H, Musshoff K et al. Report of the Committee on Hodgkin's Disease Staging. Cancer Res 1971; 31: 1860-1901.
3. Shipp MA. Prognostic factors in aggressive non-Hodgkin's lymphoma: Who has 'high-risk' disease? Blood 1994; 83 (5): 1165-73.
4. Shipp M, Harrington D, Klatt M et al. Identification of major prognostic subgroups of patients with large cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med 1986; 104: 757-65.
5. Jagannath S, Velasquez W, Tucker S et al. Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma. J Clin Oncol 1986; 4 (6): 859-65.
6. Danieu L, Wong G, Koziner B et al. Predictive model for prognosis in advanced diffuse histiocytic lymphoma. Cancer Res 1986; 46 (10): 5372-9.
7. Velasquez WS, Jagannath S, Tucker SL et al. Risk classification as the basis for clinical staging of diffuse large-cell lymphoma derived from 10-year survival data. Blood 1989; 74 (2): 551-7.
8. Hoskins P, Ng V, Spinelli J et al. Prognostic variables in patients with diffuse large-cell lymphoma treated with MACOP-B. J Clin Oncol 1991; 9 (2): 220-6.
9. Coiffier B, Gisselbrecht C, Vose J et al. Prognostic factors in aggressive malignant lymphomas: Description and validation of a prognostic index that could identify patients requiring a more intensive therapy. J Clin Oncol 1991; 9 (2): 211-9.
10. Velasquez WS, Fuller LM, Jagannath S et al. Stages I and II diffuse large cell lymphomas: Prognostic factors in long-term results with CHOP-BLEO and radiotherapy. Blood 1991; 77 (5): 942-7.
11. Hayward RL, Leonard RC, Prescott RJ (Scotland and Newcastle Lymphoma Group Therapy Working Party). A critical analysis of prognostic factors for survival in intermediate and high grade non-Hodgkin's lymphoma. Br J Cancer 1991; 63 (6): 945-52.
12. Shipp M, Harrington D, Anderson J et al. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329 (14): 987-94.
13. Bauer K, Merket D, Winter J et al. Prognostic implication of ploidy and proliferative activity in diffuse large cell lymphomas. Cancer Res 1986; 46: 3173.
14. Bino G, Silvestrini R, Costa A et al. Morphological and clinical significance of cell kinetics in non-Hodgkin's lymphomas. Basic Appl Histochem 1986; 30: 197.
15. Grogan T, Kippman S, Spier C et al. Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. Blood 1988; 71: 1157.
16. Miller T, Grogan T, Dahlberg S et al. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: A prospective Southwest Oncology Group trial. Blood 1994; 83: 1460-6.
17. Coiffier B, Brousse N, Peuchmaur M et al. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: A prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. Ann Oncol 1990; 1: 45-50.
18. Cheng AL, Chen YC, Wang CH et al. Direct comparisons of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histological grades - should peripheral T-cell lymphoma be considered separately? J Clin Oncol 1989; 7 (6): 725-31.
19. Armitage J, Greer J, Levine A et al. Peripheral T-cell lymphoma. Cancer 1989; 63: 158-63.
20. Hsu F, Levy R. Preferential use of the VH4 Ig gene family by diffuse large-cell lymphoma. Blood 1995; 86: 3072-82.
21. List A, Greco F, Vogler L. Lymphoproliferative diseases in immunocompromised hosts: The role of Epstein-Barr virus. J Clin Oncol 1988; 5: 1673-89.
22. Swinnen L, Costanzo-Nordin MR, Fisher SG et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 1990; 323: 1723.
23. Ziegler J, Meckstead J, Volberding P et al. Non-Hodgkin's lymphoma in 90 homosexual men: Relationship to generalized lympha-denopathy and acquired immunodeficiency syndrome (AIDS). N Engl J Med 1984; 311: 565.
24. Miller T, Lippman S, Epier C et al. HLA-DR (la) immune phenotype predicts outcome for patients with diffuse large cell lymphoma. J Clin Invest 1988; 82: 370.
25. List A. Spier C, Miller T et al. Deficient tumor-infiltrating T-lymphocyte response in malignant lymphoma: Relationship to HLA expression and host immunocompetence. Leukemia 1993; 7: 398.
26. Swan F Jr, Velasquez W, Tucker S et al. A new serologic staging system for large-cell lymphomas based on initial β2-microglobulin and lactage dehydrogenase levels. J Clin Oncol 1989; 7: 907.
27. Stoolman L. Adhesion molecules controlling lymphocyte migration. Cell 1989; 56: 907.
28. Picker L, Medeiros L, Weiss LM et al. Expression of lymphocyte homing receptor antigen in non-Hodgkin's lymphoma. Am J Pathol 1988; 130: 496.
29. Pals S, Horst E, Ossekoppele G et al. Expression of lymphocyte homing receptor as a mechanism of dissemination in NHL. Blood 1989; 72: 885.
30. Jalkanen S, Joensuu H, Klemi P. Prognostic value of lymphocyte homing receptor and S phase fraction in non-Hodgkin's lymphoma. Blood 1991; 75: 1549-56.
31. Horst E, Meijer C, Radaszkiewicz T et al. Adhesion molecules in the prognosis of diffuse large-cell lymphoma: Expression of a lymphocyte homing receptor (CD44): LFA-1 (CD11a/18), and ICAM-1 (CD54). Leukemia 1990; 4: 595.
32. Sy M, Guo Y-J, Stamenkovic I. Distinct effects of two CD44 isoforms on tumor growth in vivo. J Exp Med 1991; 174: 859.
33. Salles G, Zain M, Boussiotis V et al. Alternatively spliced CD44 transcripts in diffuse large cell lymphomas: Characterization and comparison with normal activated B cells and epithelial malignancies. Blood 1993; 82: 3539.
34. Stauder R, Eisterer W, Thaler J et al. CD44 variant isoforms in non-Hodgkin's lymphoma: A new independent prognostic factor. Blood 1995; 85: 2885-99.
35. Levine E, Arthur D, Frizzera G et al. Cytogenetic abnormalities predict clinical outcome in non-Hodgkin's lymphoma. Ann Intern Med 1988; 108: 14.
36. Schouten H, Sanger W, Weisenburger D et al. Chromosomal abnormalities in untreated patients with non-Hodgkin's lymphoma: Association with histology, clinical characteristics, and treatment outcome. Blood 1990; 75: 1841.
37. Cabanillas F, Pathak S, Grant G et al. Refractoriness to chemotherapy and poor survival related to abnormalities of chromosomes 17 and 7 in lymphoma. Am J Med 1989; 87: 167.
38. Rodriguez M, Ford R, Goodacre A et al. Chromosome 17p and p53 changes in lymphoma. Br J Haematol 1991; 79: 575.
39. Yunis J, Mayer M, Amesen M. Bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. N Engl J Med 1989; 320: 1047-54.
40. Offit K, Wong G, Filippa D et al. Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma: Clinical correlations. Blood 1991; 77: 1508.
41. Tsujimoto Y, Gorham J, Crossman J et al. The t(14:18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 1985; 229: 1390.
42. Bakhshi A, Jensen J, Goldman P et al. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: Clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 1985; 41: 889.
43. Cleary M, Sklar J. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA 1985; 82: 7439.
44. Cleary M, Smith S, Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell 1986; 47: 19-28.
45. Seto M, Jaeger U, Hockett R et al. Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO J 1988; 7: 123.
46. Hockenbery D, Nunez G, Milliman C et al. BCL-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334-6.
47. Nunez G, London L, Hockenbery D et al. Deregulated bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol 1990; 144: 3602-10.
48. McDonnell T, Korsmeyer S. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18). Nature 1991; 349: 254.
49. Zutter M, Hockenbery D, Silverman G et al. Immunolocalization of the bcl-2 protein within hematopoietic neoplasms. Blood 1991; 78: 1062-8.
50. Hermine O, Haioun C, Lepage E et al (Groupe d'Etude des Lymphomes de l'Adulte [GELA]). Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Blood 1996; 87: 265-72.
51. Miyashita T, Reed J. Bcl-2 gene transfer increases relative resistance of S49.1 and WEH17.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 1992; 52: 5407.
52. Miyashita T, Reed J. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993; 81: 151.
53. Minn A, Rudin C, Boise L et al. Expression of Bcl-XL can confer a multidrug resistance phenotype. Blood 1995; 86: 1903-10.
54. Offit K, Jhanwar S, Ebrahim S et al. A novel translocation associated with diffuse non-Hodgkin's lymphoma. Blood 1989; 74: 1876.
55. Bastard C, Tilly H, Lenormand B et al. Translocations involving band 3q27 and Ig gene regions in NHL. Blood 1992; 79: 2527.
56. Baron B, Nucifora G, McCabe N et al. Identification of the gene associated with the recurring chromosomal translocations t(3;14) (q27;q32) and t(3;22)(q27;q11) in B-cell lymphomas. Proc Natl Acad Sci USA 1993; 90: 5262.
57. Ye B, Lista F, Lo Coco F et al. Alterations of a zinc-finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science 1993; 262: 747-50.
58. Offit K, Lo Coco F, Louie D et al. Rearrangement of the BCL-6 gene as a prognostic marker in diffuse large-cell lymphoma. N Engl J Med 1994; 331: 74-80.
59. Koduru P, Zariwala M, Soni M et al. Deletion of cyclin-dependent kinase 4 inhibitor genes P15 and P16 in non-Hodgkin's lymphoma. Blood 1995; 86: 2900-5.
60. Gombart A, Morosetti R, Miller C et al. Deletions of the cyclin-dependent kinase inhibitor genes p161NK4A and p15INK4B in non-Hodgkin's lymphoma. Blood 1995; 86: 1534-9.
61. Houldsworth J, Mathew S, Rao P et al. REL-proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma. Blood 1996; 87: 25-9.
62. Seymour JF, Talpaz M, Cabanillas F et al. Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol 1995; 13: 575-82.